david you literally came out of nowhere. changed name on yahoo? what do you go by on google?
you seem very angry, and i'm sure it has nothing to do with my posts - maybe your failed investments. whatever, i am honored that you have followed my posts so diligently, but do you actually think i invest a lot of money on stocks that i write about? this isn't serious investing, it's a hobby. good luck.
i just read the post about not continuing. i feel bad for the patients. also, i was very wrong in thinking that the triple would work better than the abraxane/gem combination. it now make sense that dr von hoff quit talking about it quite awhile ago. one of the reason's i got out when i did. hope it works on other tumour types.
the est primary comp date is 5/2015, but i have heard/read that an update will be provided in june, and at the end of the year. does anyone know which is true and where they found the information?
dan and ez i know the difference, just surprised that people actually know the difference and didn't sell. just joking, but propthink and the street should have done another hit job.
correct. fda will not wait for full phiii results if a breast cancer drug is shown to have significantly less recurrence v placebo - and that it is safe, which neuvax has proven to be so far.
is recycling their hit job. maybe the street will investigate and find that the multiple posters are really one guy. it will be interesting to see on the financials how much gale got from propthink in their lawsuit that was settled out of court.
no, the short interest number has not been "rising every month". that is a lie that can easily be checked on the "NASDAQ website". regarding your enlightenment on the 1/31 short interest - from 1/15 to 1/31 there was an 11% increase in short interest. furthermore, the 1/31 data was available to investors on 2/11. investors took that information and starting buying, increasing the pps 11% as of yesterday. today starts a typical pull-back.
you are a genius. thanks for keeping us informed about your supposed trade by trade details. did you get much attention from your mommy?
thanks for your help. i, and i'm sure multitudes are placing their bets based on your prognostications. smearjob is apt.
twice and they didn't take. basically, phiii's enroll many more patients than phii's. statistically, this provides more accurate and comprehensive data. in pharmaceutical trials, safety and efficacy, for example. also, in the case of some trials, the phiii's target a subpopulation of the patients who were enrolled in the phii's. for example, based on the phii, gale has targeted early stage, n+, low to intermediate her2 expression breast cancer. the fda website provides information regarding clinical trials, in general. hope this helps.